OX40L and IL-2 combination strategy for gastric cancer immunotherapy
Our study demonstrates that a costimulatory immunotherapy strategy combining IL-2 and OX40L significantly enhances antitumor responses in PBMCs and TILs from GC patients, showing strong therapeutic potential as a complementary approach for the treatment of GC.
Authors
- L Li
- Bin Hu (ORCID: https://orcid.org/0000-0003-2801-9873)
- Jingjing Ma
- Hua Xie
- Yuzheng Xue
- Chengyuan Yan
- Huamin Tang
- Cheng Jin
- Junli Jia
- Emanuela Garbarino
Institutions
- Jiangnan University (CN)
- Wuxi Fourth People's Hospital (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Translational Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.21037/tcr-2025-707
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00